Nxera Pharma Co., Ltd.
4565.T · JPX
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | ¥28,835,000 | ¥12,766,000 | ¥15,569,000 | ¥17,712,000 |
| % Growth | 125.9% | -18% | -12.1% | – |
| Cost of Goods Sold | ¥7,616,000 | ¥3,102,000 | ¥926,000 | ¥933,000 |
| Gross Profit | ¥21,219,000 | ¥9,664,000 | ¥14,643,000 | ¥16,779,000 |
| % Margin | 73.6% | 75.7% | 94.1% | 94.7% |
| R&D Expenses | ¥11,816,000 | ¥10,075,000 | ¥7,454,000 | ¥5,931,000 |
| G&A Expenses | ¥16,015,000 | ¥9,965,000 | ¥4,377,000 | ¥3,940,000 |
| SG&A Expenses | ¥16,015,000 | ¥9,965,000 | ¥4,377,000 | ¥3,940,000 |
| Sales & Mktg Exp. | ¥0 | ¥0 | ¥0 | ¥0 |
| Other Operating Expenses | -¥1,189,000 | -¥850,000 | -¥624,000 | ¥3,133,000 |
| Operating Expenses | ¥26,642,000 | ¥19,190,000 | ¥11,207,000 | ¥13,004,000 |
| Operating Income | -¥5,423,000 | -¥9,526,000 | ¥2,812,000 | ¥6,908,000 |
| % Margin | -18.8% | -74.6% | 18.1% | 39% |
| Other Income/Exp. Net | ¥761,000 | -¥1,154,000 | -¥1,734,000 | -¥6,475,000 |
| Pre-Tax Income | -¥4,662,000 | -¥10,680,000 | ¥1,078,000 | ¥433,000 |
| Tax Expense | ¥176,000 | -¥3,487,000 | ¥696,000 | -¥584,000 |
| Net Income | -¥4,838,000 | -¥7,193,000 | ¥382,000 | ¥1,017,000 |
| % Margin | -16.8% | -56.3% | 2.5% | 5.7% |
| EPS | -53.92 | -87.17 | 4.67 | 12.53 |
| % Growth | 38.1% | -1,966.6% | -62.7% | – |
| EPS Diluted | -53.92 | -87.17 | 4.63 | 12.4 |
| Weighted Avg Shares Out | 89,726 | 82,517 | 81,785 | 81,187 |
| Weighted Avg Shares Out Dil | 89,732 | 82,517 | 82,590 | 82,006 |
| Supplemental Information | – | – | – | – |
| Interest Income | ¥1,544,000 | ¥1,341,000 | ¥663,000 | ¥199,000 |
| Interest Expense | ¥783,000 | ¥2,495,000 | ¥756,000 | ¥3,797,000 |
| Depreciation & Amortization | ¥3,984,000 | ¥2,478,000 | ¥1,345,000 | ¥1,278,000 |
| EBITDA | ¥105,000 | -¥5,707,000 | ¥3,567,000 | ¥2,189,000 |
| % Margin | 0.4% | -44.7% | 22.9% | 12.4% |